PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.13 EPS

PepGen (NASDAQ:PEPG) posted its quarterly earnings data on Monday. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.13, Zacks reports.

PepGen Stock Down 25.3 %

Shares of NASDAQ PEPG opened at $1.71 on Wednesday. The company has a market cap of $55.75 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. PepGen has a 12-month low of $1.16 and a 12-month high of $19.30. The firm’s 50-day simple moving average is $2.46 and its 200 day simple moving average is $5.78.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PEPG shares. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a report on Monday, December 16th. Wedbush lowered their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of PepGen in a research note on Monday.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.